High-Throughput MicroRNA Profiling of Vitreoretinal Lymphoma: Vitreous and Serum MicroRNA Profiles Distinct from Uveitis.
machine learning
microRNA
uveitis
vitreoretinal lymphoma
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
12 Jun 2020
12 Jun 2020
Historique:
received:
07
05
2020
revised:
06
06
2020
accepted:
09
06
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Vitreoretinal lymphoma (VRL) is a non-Hodgkin lymphoma of the diffuse large B cell type (DLBCL), which is an aggressive cancer causing central nervous system related mortality. The pathogenesis of VRL is largely unknown. The role of microRNAs (miRNAs) has recently acquired remarkable importance in the pathogenesis of many diseases including cancers. Furthermore, miRNAs have shown promise as diagnostic and prognostic markers of cancers. In this study, we aimed to identify differentially expressed miRNAs and pathways in the vitreous and serum of patients with VRL and to investigate the pathogenesis of the disease. Vitreous and serum samples were obtained from 14 patients with VRL and from controls comprising 40 patients with uveitis, 12 with macular hole, 14 with epiretinal membrane, 12 healthy individuals. The expression levels of 2565 miRNAs in serum and vitreous samples were analyzed. Expression of the miRNAs correlated significantly with the extracellular matrix (ECM) ‒receptor interaction pathway in VRL. Analyses showed that miR-326 was a key driver of B-cell proliferation, and miR-6513-3p could discriminate VRL from uveitis. MiR-1236-3p correlated with vitreous interleukin (IL)-10 concentrations. Machine learning analysis identified miR-361-3p expression as a discriminator between VRL and uveitis. Our findings demonstrate that aberrant microRNA expression in VRL may affect the expression of genes in a variety of cancer-related pathways. The altered serum miRNAs may discriminate VRL from uveitis, and serum miR-6513-3p has the potential to serve as an auxiliary tool for the diagnosis of VRL.
Identifiants
pubmed: 32545709
pii: jcm9061844
doi: 10.3390/jcm9061844
pmc: PMC7356511
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Front Genet. 2019 Dec 13;10:1274
pubmed: 31921311
Retina. 2018 Apr;38(4):773-781
pubmed: 29135797
Med Oncol. 2014 Dec;31(12):306
pubmed: 25370733
Blood. 2019 Aug 22;134(8):709-712
pubmed: 31292111
J Clin Lab Anal. 2019 Nov;33(9):e23003
pubmed: 31541491
Clin Ophthalmol. 2019 Feb 14;13:353-364
pubmed: 30858685
Cancer. 2005 Aug 1;104(3):591-7
pubmed: 15973665
Acta Ophthalmol. 2020 Jan 29;:
pubmed: 31994839
Ophthalmology. 1999 Dec;106(12):2291-5
pubmed: 10599659
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
Cell Death Dis. 2018 Jul 24;9(8):807
pubmed: 30042387
Int J Mol Sci. 2019 Mar 15;20(6):
pubmed: 30884772
J Rheumatol. 2015 Oct;42(10):1746-1751
pubmed: 26233505
J Clin Pathol. 2017 Jan;70(1):9-14
pubmed: 27798082
Biochem Biophys Res Commun. 2019 Mar 19;510(4):594-600
pubmed: 30739786
Oncol Lett. 2019 Jan;17(1):230-246
pubmed: 30655760
PLoS One. 2008 Sep 05;3(9):e3148
pubmed: 18773077
Neuro Oncol. 2013 Jun;15(6):727-34
pubmed: 23482670
Cancer Cell Int. 2018 May 1;18:66
pubmed: 29743816
Cancer Cell Int. 2020 Feb 13;20:49
pubmed: 32082079
J Mol Diagn. 2013 Nov;15(6):827-34
pubmed: 23988620
Brain Res. 1992 Mar 13;575(1):57-62
pubmed: 1504780
Blood. 2015 Jul 2;126(1):76-9
pubmed: 25900979
Molecules. 2014 Sep 17;19(9):14723-81
pubmed: 25232701
J Clin Pathol. 2003 Oct;56(10):747-52
pubmed: 14514777
Exp Ther Med. 2019 Feb;17(2):1154-1162
pubmed: 30679988
JAMA Netw Open. 2019 May 3;2(5):e194573
pubmed: 31125107
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
pubmed: 14973191
Exp Hematol. 2018 Feb;58:27-34.e1
pubmed: 29158064
Invest Ophthalmol Vis Sci. 2012 Aug 09;53(9):5395-402
pubmed: 22789925
Exp Hematol. 2010 Jan;38(1):38-45
pubmed: 19857547
Medicine (Baltimore). 2017 Sep;96(39):e7952
pubmed: 28953617
Exp Cell Res. 2016 May 1;343(2):135-147
pubmed: 27090017
Drug Des Devel Ther. 2015 Sep 16;9:5225-35
pubmed: 26396496
Onco Targets Ther. 2019 Nov 20;12:9957-9964
pubmed: 31819492
Biol Psychiatry. 2011 Jan 15;69(2):188-93
pubmed: 21183010
Int J Mol Sci. 2017 Nov 11;18(11):
pubmed: 29137139
JAMA Ophthalmol. 2018 Oct 1;136(10):1098-1104
pubmed: 30027272
Onco Targets Ther. 2016 Mar 29;9:1801-12
pubmed: 27099513
Oncol Rep. 2017 Mar;37(3):1469-1476
pubmed: 28184923
Sci Rep. 2018 Aug 23;8(1):12681
pubmed: 30140011
Nat Rev Clin Oncol. 2018 Sep;15(9):541-563
pubmed: 29784926
Eur J Haematol. 2019 Feb;102(2):191-196
pubmed: 30390359
Curr Opin Cell Biol. 2008 Apr;20(2):214-21
pubmed: 18329869
Mol Cell Biochem. 2018 Dec;449(1-2):145-156
pubmed: 29700729
Exp Ther Med. 2017 Nov;14(5):4489-4496
pubmed: 29067124
Front Genet. 2019 Mar 18;10:197
pubmed: 30936892
Biochem Biophys Res Commun. 2017 Oct 21;492(3):461-467
pubmed: 28842254
Neoplasma. 2017;64(6):824-833
pubmed: 28895406
Stem Cells Dev. 2017 May 1;26(9):656-677
pubmed: 28103766
World J Gastroenterol. 2015 Mar 21;21(11):3245-55
pubmed: 25805931
J Clin Exp Hematop. 2016;56(2):71-78
pubmed: 27980305
Leuk Res. 2013 Nov;37(11):1420-8
pubmed: 24054860
Blood. 2017 Jun 8;129(23):3130-3133
pubmed: 28389463
FEBS J. 2012 Oct;279(20):3800-12
pubmed: 22883469
Oncol Res. 2017 Sep 21;25(8):1269-1282
pubmed: 28117027
Ocul Immunol Inflamm. 2004 Mar;12(1):7-16
pubmed: 15209459
BMC Mol Cell Biol. 2019 Aug 27;20(1):39
pubmed: 31455213
Am J Physiol Cell Physiol. 2019 Mar 1;316(3):C299-C311
pubmed: 30462539
Jpn J Ophthalmol. 2012 Sep;56(5):432-5
pubmed: 22752308
Mol Cancer. 2019 Jan 21;18(1):13
pubmed: 30665425
Int J Cancer. 2007 Sep 1;121(5):1156-61
pubmed: 17487835
Leukemia. 1999 Sep;13(9):1448-55
pubmed: 10482998
Nat Med. 2014 Jun;20(6):599-606
pubmed: 24813251
Cell Mol Biol Lett. 2019 Jun 6;24:38
pubmed: 31182966
Oncotarget. 2015 Jun 20;6(17):15035-49
pubmed: 25909227
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Apr 28;43(4):421-427
pubmed: 29774880
Jpn J Ophthalmol. 2012 Jul;56(4):383-9
pubmed: 22661396
J Res Med Sci. 2019 Feb 25;24:10
pubmed: 30988678
Am J Ophthalmol. 2014 Mar;157(3):728-34
pubmed: 24345320
Oncol Rep. 2014 Sep;32(3):1029-36
pubmed: 25016979
Jpn J Ophthalmol. 2007 Jan-Feb;51(1):41-4
pubmed: 17295139
Leukemia. 2018 Mar;32(3):703-711
pubmed: 29135973
Oncol Rep. 2016 Dec;36(6):3371-3378
pubmed: 27779704
Int J Retina Vitreous. 2018 May 7;4:18
pubmed: 29760948
FEBS Open Bio. 2020 Jan 27;:
pubmed: 31984680
Ann Hematol. 2016 Mar;95(4):593-601
pubmed: 26732884
Ophthalmology. 2013 May;120(5):991-6
pubmed: 23380473
Ocul Immunol Inflamm. 2009 May-Jun;17(3):133-41
pubmed: 19585354